Decellularized Amniotic Membrane Hydrogel for Scalable Cell Scaffolds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fully synthetic hydrogels lack essential growth factors for cell proliferation and exhibit poor biocompatibility, limiting their effectiveness in cell culture and clinical applications, while existing matrix hydrogels like EHS are difficult to scale and have tumor-derived characteristics.
Innovation Solution
A method is developed to prepare a decellularized amniotic membrane matrix hydrogel by decellularizing and freeze-drying amniotic membranes, preserving collagen, fibronectin, and glycoproteins, and mixing with pepsin and PBS to create a biocompatible hydrogel.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If fully synthetic hydrogels are used, then structural uniformity and material stability are improved, but biocompatibility and cell proliferation support are worsened
Solution Approach 1:
The patent uses decellularized amniotic membrane as a natural polymer component combined with synthetic hydrogel matrix to create a composite material that provides both structural stability and biological activity including growth factors and extracellular matrix components essential for cell proliferation
Solution Approach 2:
The hydrogel is designed with localized biological components distributed throughout the matrix, creating regions with enhanced biocompatibility and cell adhesion properties while maintaining overall structural uniformity of the synthetic base material
2Reliability
If EHS matrix hydrogels are used, then cell culture performance is improved, but scalability and mass production are worsened
Solution Approach 1:
The patent extracts and utilizes the beneficial extracellular matrix components and growth factors from amniotic membrane through decellularization, separating the functional biological elements from the cellular components that limit scalability, thereby enabling mass production while maintaining cell culture performance
Solution Approach 2:
The amniotic membrane source material is readily available, cost-effective, and can be processed into hydrogels that do not require long-term cell maintenance, enabling scalable production compared to EHS gels that require ongoing osteosarcoma cell culture
3Reliability
If EHS matrix hydrogels are used, then matrix hydrogel functionality is improved, but clinical application prospects are worsened due to tumor-derived characteristics
Solution Approach 1:
The patent extracts only the beneficial extracellular matrix components and growth factors from amniotic membrane while removing all cellular material through decellularization, eliminating tumor-derived characteristics while preserving matrix hydrogel functionality for clinical applications
Solution Approach 2:
The patent converts the potential harm of using tumor-derived materials into a benefit by selecting a non-tumorous source (amniotic membrane) that provides equivalent or superior biological functionality without the harmful genetic and immunological risks associated with EHS gel cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The decellularized amniotic membrane matrix hydrogel mimics the in vivo microenvironment, supporting cell adhesion and growth, facilitating tissue engineering scaffolds, and serving as a drug carrier, with excellent biocompatibility and clinical potential.
Implementation Method 1
freezing is conducted to form ice particles inside the cells, which are then thawed at room temperature (or 40° C.). The freezing increases the salt concentration of the remaining cytosol, causing cell swelling and rupture
Implementation Method 2
The freezing increases the salt concentration of the remaining cytosol, causing cell swelling and rupture
Implementation Method 3
freeze-drying the decellularized amniotic membrane powder obtained in step (2) to yield freeze-dried decellularized amniotic membrane powder
Data Source
AI summary
Provided are a decellularized amniotic membrane matrix hydrogel and its preparation method, which includes the following steps: pre-treatment of an amniotic membrane tissue, washing, decellularization, grinding, freeze-drying, digestion, and acid-base neutralization processes. The decellularized amniotic membrane matrix hydrogel provided in this disclosure retains components such as collagen, fibronectin, and glycoproteins from the amniotic membrane while removing viable cells, thereby reducing its immunogenicity at the source. The decellularized amniotic membrane matrix hydrogel may mimic the microenvironment in which cells exist in vivo, providing the necessary support and signals for cell adhesion and growth. It can be used to construct tissue engineering scaffolds, supporting directed cell growth and tissue regeneration. Furthermore, the decellularized amniotic membrane matrix hydrogel may also serve as a drug carrier for in vivo drug release and therapy, demonstrating significant potential for application in medical research and clinical settings.